LOGIN
Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment
August 2018
Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Dronabinol is a safe long-term treatment option for neuropathic pain patients
Eur Neurol. 2017;78(5-6):320-329.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
240 patients who had neuropathic pain that was associated with multiple sclerosis (MS) were randomly assigned to receive either dronabinol 7.5-15.0 mg daily for 16 weeks, or its respective placebo with the identical schedule. No significant differences in pain reduction and quality of life improvement were found in patients that received dronabinol compared to those that received placebo. In a fol...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.